Hepatorenal Syndrome Treatment Market Size, Share , Latest Trends, Key Players And Forecast To 2033

The hepatorenal syndrome treatment market size has grown strongly in recent years. It will grow from $13.85 billion in 2023 to $14.67 billion in 2024 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to automotive industry growth, aerospace sector requirements, advantages in material utilization, improved mechanical properties, stringent industry standards, efficiency and precision gains..

The hepatorenal syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $18.56 billion in 2028 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to rise in renewable energy projects, growing demand for high-performance alloys, focus on sustainable manufacturing, expansion of oil and gas exploration, demand for high-performance components.. Major trends in the forecast period include integration of industry 4.0 technologies, research and development in forging techniques, customization for specific applications, automation in forging processes, innovations in heating and cooling technologies..

Market Overview -
Hepatorenal syndrome (HRS) is a multiorgan disorder characterized by acute kidney injury in patients with severe liver disease. Patients with this syndrome display signs and symptoms of liver failure in addition to decreased urination when they become oliguric.

Download Free Sample of Report -

https://www.thebusinessresearchcompany.com/sample.aspx?id=10414&type=smp

Rising Incidences Of Liver Damage And Cirrhosis Fueling Growth In The Hepatorenal Syndrome Treatment Market
An increase in the incidences of patients with liver damage or cirrhosis is expected to propel the growth of the hepatorenal syndrome treatment market going forward. Cirrhosis is a severe form of liver disease in which scar tissue permanently replaces good liver tissue. Hepatorenal syndrome treatment aims to retain the patient's kidney function while alleviating symptoms and adverse effects of the disorder. These strategies may help to improve overall health and make you a better candidate for liver transplant surgery. For instance, in September 2022, according to a Fact Sheet published by the Centers for Disease Control and Prevention, a US-based Government agency, the number of adults with diagnosed liver disease in the US was 4.5 million. Moreover, according to Medscape, a website providing access to medical information, states ALD-related fatalities increased by 17.6% between 2019 and 2021, whereas NAFLD-related deaths climbed by 14.5%. Therefore, the increase in the incidences of patients with liver damage or cirrhosis is driving the growth of the hepatorenal syndrome treatment market.

Competitive Landscape -
Major companies operating in the hepatorenal syndrome treatment market report are Becton Dickinson and Company, BioVie Inc., Cumberland Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Orphan Therapeutics LLC, ESP Pharma Inc., PharmaIN Corporation, Baxter International Inc., La Jolla Pharmaceutical Company, Noorik Biopharmaceuticals AG, Novartis AG, Zydus Lifesciences limited, Mount Sinai Health System Inc., NYU Langone Health, Max Healthcare Institute Limited, 3A Composites, Ocelot Bio Inc., New Medicon Pharma Lab Private Limited, Allergan plc, Arrowhead Pharmaceuticals, Stealth BioTherapeutics Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Inc., Johnson & Johnson, Boehringer Ingelheim GmbH, Conatus Pharmaceuticals Inc., Catalyst Pharmaceuticals Inc., Bayer AG, Gilead Sciences Inc.

Increasing Emphasis On Research And Development Driving Advances In Hepatorenal Syndrome Treatment
Increasing research and development activities for hepatorenal syndrome treatment is a key trend gaining popularity in the hepatorenal syndrome treatment market. Companies operating in the hepatorenal syndrome treatment market are now focusing more on research and development to sustain their position in the market. For instance, in September 2022, Mallinckrodt Pharmaceuticals, an Ireland-based company specializing in developing, manufacturing, and distributing specialty products and therapies, announced the FDA approval for Terlivaz for an injection that helps adults with hepatorenal syndrome's kidney function. The Phase 3 CONFIRM trial, the largest-ever prospective research (n=300) done to evaluate the safety and efficacy of terlipressin in patients with HRS type 1 (HRS-1) in the U.S. and Canada, was a significant factor in the FDA's approval. Verified HRS Reversal, measured as an improvement in renal function, avoiding the need for dialysis, and short-term survival, was achieved by the CONFIRM trial's primary endpoint (p=0.012).

Browse Full Report @

https://www.thebusinessresearchcompany.com/report/hepatorenal-syndrome-treatment-global-market-report

Key Segments -

The hepatorenal syndrome treatment market covered in this report is segmented -

1) By Type: Type 1 Hepatorenal Syndrome, Type 2 Hepatorenal Syndrome
2) By Treatment: Therapeutics, Surgical Treatment
3) By End-User: Hospitals And Clinics, Ambulatory Surgical Centers, Academic And Research Institutes, Other End-Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.